Bronchoscopic Cryoablation Combined With Chemo-Immunotherapy in NSCLC With Central Airway Obstruction

Inclusion Criteria: * Understand the requirements and contents of the clinical trial and provide a signed and dated informed consent form. * Age≥18 years and≤80 years. * Histologically or cytologically confirmed and documented locally advanced or metastatic non-small cell lung cancer (NSCLC) without prior systemic therapy and EGFR-sensitive mutations (19del, L858R and T790M). * Presence of a palliative treatment lesion in the central airway that is amenable to ablation, endoscopically assessed to be≥1/3 obstruction, such as primary or metastatic malignancy to the trachea, main bronchi, intermediate bronchi, or segmental bronchi. corresponding respiratory symptoms or obstructive pneumonia is permission to be included. * Eastern Cooperative Oncology Group (ECOG) ： 0-2. * Predicted survival ≥ 12 weeks. * Adequate bone marrow hematopoiesis and organ function (cardiac function, hepatic, and renal function). * Presence of measurable lesions according to RECIST 1.1 criteria. * Subjects with stable brain metastases may be included in the study. Exclusion Criteria: * Histological diagnosis of small cell, large cell lung cancer; mixed tumors will be classified based on the primary cell type; if the primary component is small cell, large cell, or neuroendocrine carcinoma, the subject will not be eligible for enrollment; however, mixed adenocarcinoma-squamous cell carcinoma is acceptable. Subjects with driver gene mutations are generally not eligible for enrollment. * Malignant centra…